Deals In Depth: November 2011

By Amanda Micklus / Email the Author / IN VIVO January 2012, Vol. 30, No. 1
Deals In Depth / Word Count: 970 / Article # 2012800001

Executive Summary

Otsuka and Lundbeck signed a long-term CNS collaboration worth $1.4 billion. Gilead spent $10.4 billion on HCV company Pharmasset, the largest amount ever paid for a clinical-stage biotech. Late venture financing and follow-on public offerings represented half of the $945 million that biopharma companies raised. Later-stage rounds were also popular with device companies, which took in $156 million through that financing type, 66% of the $236 million raised.